Nicholas Basta

Growing digitization of patient data could break the threshold to better adherence to medication therapies

How the many anticounterfeiting measures on the market today could turn into a means of connecting with patients

More and more parts of the healthcare industry are connecting

Old software and poor data quality cause both revenue losses and extra expense to reconcile claims. Will serialized packages provide an eventual cure?

Latest 10-year BLS projection sees moderate growth in US employment—except for ‘top executives’

The signs are apparent that there is organized criminal activity focused on pharma logistics By Nicholas Basta

FDA struggles with the new world of social media

As more temperature-sensitive product move around the globe, industry and regulators intensify their efforts to improve packaging and manage safe shipping

A potential savings of $46 billion in working capital is available to the industry, says Accenture study

TAKE Supply Chain helps Three Rivers Pharmaceuticals organize its distribution and shipping operations

The desire to compare drugs’ efficacy is shifting from a purely medical decision to a financial one

As legislative mandates have receded, manufacturers must undertake their own initiatives for protecting against counterfeits and diversion

Preventable medical and medication errors should figure more prominently in the current debate on healthcare reform

While drug spending by clients averaged 3.3% last year, higher spending growth is predicted for the next three years

Manufacturers have a growing number of service offerings to reach patients with adherence advice

Rising globalization of biopharma puts a spotlight on shipping processes and regulatory clearances

Claims of the death of the pharma sales rep occupation have been greatly exaggerated

Innovative middleware lowers the administrative burden of managing large databases

American Recovery and Reinvestment Act allocates $18 billion for HIT

Bipartisan group of senators sponsor a revived drug-importation bill

While California’s e-pedigree initiative sits on a shelf, actions in Washington and Brussels point to renewed efforts for track-and-trace of pharmaceuticals

FDA’s management of drug and device safety enters GAO’s biennial watch list